INSMED Inc. Files 8-K Report
Ticker: INSM · Form: 8-K · Filed: 2024-06-13T00:00:00.000Z
Sentiment: neutral
Topics: sec-filing, 8-k, routine-report
TL;DR
INSMED filed a routine 8-K, no major news.
AI Summary
On June 12, 2024, INSMED Inc. filed an 8-K report to disclose other events. The filing does not contain specific financial figures or significant business updates beyond the routine reporting of an 8-K.
Why It Matters
This filing indicates INSMED Inc. is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain information that suggests an immediate change in risk for the company.
Key Players & Entities
- INSMED Inc. (company) — Registrant
- Virginia (jurisdiction) — State of incorporation
- 000-30739 (filing_id) — SEC File Number
- 54-1972729 (tax_id) — IRS Employer Identification No.
- 700 US Highway 202/206 Bridgewater, New Jersey 08807 (address) — Principal executive offices
- June 12, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by INSMED Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' as of June 12, 2024, fulfilling INSMED Inc.'s current reporting obligations to the SEC.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is June 12, 2024.
What is INSMED Inc.'s state of incorporation and principal executive office location?
INSMED Inc. is incorporated in Virginia and its principal executive offices are located at 700 US Highway 202/206, Bridgewater, New Jersey 08807.
Does this 8-K filing disclose any specific financial transactions or material business developments?
Based on the provided text, this 8-K filing is categorized under 'Other Events' and does not explicitly disclose specific financial transactions or material business developments.
What is the SEC file number for INSMED Inc.?
The SEC file number for INSMED Inc. is 000-30739.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2024-06-13 08:00:32
Key Financial Figures
- $0.01 — h registered Common Stock, par value $0.01 per share INSM Nasdaq Global Select
Filing Documents
- ef20031070_8k.htm (8-K) — 25KB
- 0001140361-24-029955.txt ( ) — 155KB
- insm-20240612.xsd (EX-101.SCH) — 4KB
- insm-20240612_lab.xml (EX-101.LAB) — 21KB
- insm-20240612_pre.xml (EX-101.PRE) — 16KB
- ef20031070_8k_htm.xml (XML) — 4KB
01 – Other Events
ITEM 8.01 – Other Events. As previously disclosed, on March 8, 2024, Insmed Incorporated (the "Company") received notice of the exercise by AstraZeneca AB ("AstraZeneca") of its second and final option (the "Final Option") under the License Agreement, dated October 4, 2016, by and between the Company and AstraZeneca (the "License Agreement"), to further develop and, if approved, commercialize brensocatib in the indications of chronic obstructive pulmonary disease ("COPD") or asthma. On June 12, 2024, the negotiation period following such exercise of the Final Option expired. No agreement was reached between the Company and AstraZeneca to permit AstraZeneca to further develop and, if approved, commercialize brensocatib in the indications of COPD or asthma. The Company retains full worldwide development and commercialization rights for brensocatib in all indications other than COPD or asthma and AstraZeneca has no further development or commercialization rights for brensocatib in COPD, asthma or any other indication.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 13, 2024 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary